文献速递造血干细胞移植与细胞治疗

慢性GVHD与晚发急性GVHD的免疫特征差异:ABLE/PBMTC 1202研究

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.
PubMed 文献 · Blood · 2020-01-01

该研究分析302例儿童HSCT后第100天外周血免疫细胞与血浆标志物,按NIH共识标准诊断GVHD。cGVHD与L-aGVHD均见过渡B细胞减少和细胞毒性NK细胞增加,cGVHD另有活化T细胞、初始Th及细胞毒性T细胞增加、CD56bright调节性NK细胞丢失及ST2和可溶性CD13升高。

要点

  • cGVHD与L-aGVHD共享过渡B细胞减少和细胞毒性NK细胞增加。
  • cGVHD特有活化T细胞增加、CD56bright调节性NK细胞丢失及ST2和sCD13升高。
  • 免疫异常从无GVHD到L-aGVHD再到cGVHD呈递进模式。

核心结论

  • cGVHD与L-aGVHD存在共享及各自的免疫特征异常,cGVHD免疫异常模式最复杂。

研究设计与样本

  • ABLE/PBMTC1202研究(NCT02067832)纳入302例儿童HSCT患者,241例可评估为L-aGVHD、cGVHD、活动性L-aGVHD或cGVHD及无cGVHD/L-aGVHD。
  • 于HSCT后第100天分析外周血免疫细胞与血浆标志物,按NIH共识标准诊断cGVHD。

主要发现

  • 仅具非NIH-CC特征但被裁定委员会判为cGVHD者,免疫特征与NIH-CC cGVHD相似。
  • cGVHD与L-aGVHD均见过渡B细胞减少和细胞毒性NK细胞增加。
  • cGVHD另见活化T细胞增加、初始Th及细胞毒性T细胞增加、CD56bright调节性NK细胞丢失、ST2和可溶性CD13升高。
  • 第114天前活动性L-aGVHD另见初始Th、初始Treg细胞群及细胞因子异常;活动性cGVHD见PD-1-记忆Treg增加、PD-1+记忆Treg减少。
  • 无监督分析显示免疫异常从无cGVHD/L-aGVHD到L-aGVHD再到cGVHD呈递进模式。

关键数值与推荐

  • 标志物差异需同时满足ROC曲线下面积≥0.60、P≤.05、效应比≥1.3或≤0.75。

临床怎么用

  • 全面免疫特征分析有助于理解如何减少L-aGVHD和cGVHD。

局限性

  • 需在成人和儿童队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human graft-versus-host disease (GVHD) biology beyond 3 months after hematopoietic stem cell transplantation (HSCT) is complex. The Applied Biomarker in Late Effects of Childhood Cancer study (ABLE/PBMTC1202, NCT02067832) evaluated the immune profiles in chronic GVHD (cGVHD) and late acute GVHD (L-aGVHD). Peripheral blood immune cell and plasma markers were analyzed at day 100 post-HSCT and correlated with GVHD diagnosed according to the National Institutes of Health consensus criteria (NIH-CC) for cGVHD. Of 302 children enrolled, 241 were evaluable as L-aGVHD, cGVHD, active L-aGVHD or cGVHD, and no cGVHD/L-aGVHD. Significant marker differences, adjusted for major clinical factors, were defined as meeting all 3 criteria: receiver-operating characteristic area under the curve ≥0.60, P ≤ .05, and effect ratio ≥1.3 or ≤0.75. Patients with only distinctive features but determined as cGVHD by the adjudication committee (non-NIH-CC) had immune profiles similar to NIH-CC. Both cGVHD and L-aGVHD had decreased transitional B cells and increased cytolytic natural killer (NK) cells. cGVHD had additional abnormalities, with increased activated T cells, naive helper T (Th) and cytotoxic T cells, loss of CD56bright regulatory NK cells, and increased ST2 and soluble CD13. Active L-aGVHD before day 114 had additional abnormalities in naive Th, naive regulatory T (Treg) cell populations, and cytokines, and active cGVHD had an increase in PD-1- and a decrease in PD-1+ memory Treg cells. Unsupervised analysis appeared to show a progression of immune abnormalities from no cGVHD/L-aGVHD to L-aGVHD, with the most complex pattern in cGVHD. Comprehensive immune profiling will allow us to better understand how to minimize L-aGVHD and cGVHD. Further confirmation in adult and pediatric cohorts is needed.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Schultz KR, Kariminia A, Ng B, et al. Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies. Blood. 2020. PMID: 32047896. doi:10.1182/blood.2019003186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。